NASDAQ:FNCH Finch Therapeutics Group (FNCH) Stock Price, News & Analysis → Wall Street Legend Warns: 'A Strange Day Is Coming to America' (From Chaikin Analytics) (Ad) Free FNCH Stock Alerts $1.21 -0.59 (-32.78%) (As of 05:38 PM ET) Add Compare Share Share Today's Range$0.80▼$1.6950-Day Range$1.80▼$3.1052-Week Range$0.80▼$16.74Volume111,960 shsAverage Volume47,212 shsMarket Capitalization$1.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Finch Therapeutics Group alerts: Email Address Finch Therapeutics Group MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.83% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 3 Articles This WeekInsider TradingSelling Shares$17,070 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.43 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Finch Therapeutics Group.Read more about Finch Therapeutics Group's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.83% of the float of Finch Therapeutics Group has been sold short.Short Interest Ratio / Days to CoverFinch Therapeutics Group has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Finch Therapeutics Group has recently decreased by 27.27%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldFinch Therapeutics Group does not currently pay a dividend.Dividend GrowthFinch Therapeutics Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FNCH. Previous Next 2.7 News and Social Media Coverage News SentimentFinch Therapeutics Group has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Finch Therapeutics Group this week, compared to 0 articles on an average week.Search Interest1 people have searched for FNCH on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Finch Therapeutics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,070.00 in company stock.Percentage Held by Insiders44.90% of the stock of Finch Therapeutics Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.77% of the stock of Finch Therapeutics Group is held by institutions.Read more about Finch Therapeutics Group's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Finch Therapeutics Group is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Finch Therapeutics Group is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFinch Therapeutics Group has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Finch Therapeutics Group's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsWall Street Legend Warns: "A Strange Day Is Coming to America"Get Your Cash Out of U.S. Banks Immediately Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making.Click here to learn more. About Finch Therapeutics Group Stock (NASDAQ:FNCH)Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Read More FNCH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FNCH Stock News HeadlinesMay 21, 2024 | americanbankingnews.comFinch Therapeutics Group (NASDAQ:FNCH) Trading Up 15.5%April 14, 2024 | fool.comFinch Therapeutics Group (NASDAQ: FNCH)March 25, 2024 | investorplace.comFNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q4 2023March 7, 2024 | investing.comFinch Therapeutics Group Inc (FNCH)February 22, 2024 | benzinga.comFinch Therapeutics Gr Stock (NASDAQ:FNCH), Short Interest ReportNovember 5, 2023 | morningstar.comFinch Therapeutics Group Inc FNCHAugust 21, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Finch Therapeutics Group (FNCH)June 9, 2023 | finanznachrichten.deFinch Therapeutics Group, Inc.: Finch Announces Reverse Stock Split of Common StockMay 13, 2023 | msn.comHC Wainwright & Co. Reiterates Finch Therapeutics Group (FNCH) Buy RecommendationMay 12, 2023 | marketwatch.com8-K: Finch Therapeutics Group, Inc.May 10, 2023 | finanznachrichten.deFinch Therapeutics Group, Inc.: Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 10, 2023 | finance.yahoo.comFinch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesApril 25, 2023 | finance.yahoo.comFinch Therapeutics Announces Executive Leadership TransitionsApril 22, 2023 | finanznachrichten.deFINCH THERAPEUTICS GROUP INCApril 18, 2023 | finance.yahoo.comFinch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License AgreementApril 4, 2023 | markets.businessinsider.comFinch Therapeutics Group (FNCH) Gets a Buy from H.C. WainwrightApril 3, 2023 | finanznachrichten.deFinch Therapeutics Group, Inc.: Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesMarch 25, 2023 | msn.comLooking Into Finch Therapeutics Group's Return On Capital EmployedMarch 25, 2023 | finance.yahoo.comFinch Therapeutics Group Full Year 2022 Earnings: Misses ExpectationsMarch 23, 2023 | finance.yahoo.comFinch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesJanuary 24, 2023 | finance.yahoo.comMicrobiome startup cuts 95% of remaining staff in 3rd layoff in 9 monthsJanuary 24, 2023 | marketwatch.comFinch Therapeutics Ending Phase 3 Study, Cutting Most of Workforce >FNCHJanuary 24, 2023 | finance.yahoo.comFinch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other AssetsNovember 11, 2022 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Kezar Life Sciences (KZR), RVL Pharmaceuticals (RVLP)November 11, 2022 | finance.yahoo.comFinch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial ResultsSee More Headlines Receive FNCH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today5/28/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FNCH CUSIPN/A CIK1733257 Webwww.finchtherapeutics.com Phone617-229-6499FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($10.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,750,000.00 Net MarginsN/A Pretax Margin-73,098.12% Return on Equity-68.11% Return on Assets-28.10% Debt Debt-to-Equity RatioN/A Current Ratio6.05 Quick Ratio6.05 Sales & Book Value Annual Sales$110,000.00 Price / Sales18.44 Cash FlowN/A Price / Cash FlowN/A Book Value$14.25 per share Price / Book0.09Miscellaneous Outstanding Shares1,610,000Free Float885,000Market Cap$2.03 million OptionableNo Data Beta0.46 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Matthew P. Blischak J.D. (Age 61)President, Secretary & CEO Comp: $558.81kMr. Lance Thibault CPA (Age 58)Chief Financial Officer Comp: $168.79kMr. James S. Sigler MBA (Age 63)Executive Vice President of CMC Key Competitors22nd Century GroupNASDAQ:XXIICoeptis TherapeuticsNASDAQ:COEPOrganovoNASDAQ:ONVOGenetic TechnologiesNASDAQ:GENEBioCardiaNASDAQ:BCDAView All CompetitorsInsiders & InstitutionsLake Street Advisors Group LLCBought 21,206 shares on 5/14/2024Ownership: 1.317%Jeffery A. SmisekSold 6,642 sharesTotal: $17,069.94 ($2.57/share)Jeffery A SmisekSold 1,470 sharesTotal: $5,350.80 ($3.64/share)View All Insider TransactionsView All Institutional Transactions FNCH Stock Analysis - Frequently Asked Questions How have FNCH shares performed in 2024? Finch Therapeutics Group's stock was trading at $3.61 on January 1st, 2024. Since then, FNCH stock has decreased by 66.5% and is now trading at $1.21. View the best growth stocks for 2024 here. Are investors shorting Finch Therapeutics Group? Finch Therapeutics Group saw a drop in short interest in May. As of May 15th, there was short interest totaling 19,200 shares, a drop of 27.3% from the April 30th total of 26,400 shares. Based on an average daily trading volume, of 65,800 shares, the short-interest ratio is currently 0.3 days. Currently, 2.8% of the company's stock are sold short. View Finch Therapeutics Group's Short Interest. When is Finch Therapeutics Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our FNCH earnings forecast. How were Finch Therapeutics Group's earnings last quarter? Finch Therapeutics Group, Inc. (NASDAQ:FNCH) released its quarterly earnings data on Monday, March, 25th. The company reported ($1.89) EPS for the quarter. When did Finch Therapeutics Group's stock split? Finch Therapeutics Group's stock reverse split before market open on Monday, June 12th 2023. The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Finch Therapeutics Group IPO? Finch Therapeutics Group (FNCH) raised $101 million in an initial public offering on Friday, March 19th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO. Who are Finch Therapeutics Group's major shareholders? Finch Therapeutics Group's stock is owned by many different institutional and retail investors. Top institutional investors include Lake Street Advisors Group LLC (1.32%). Insiders that own company stock include Jeffery A Smisek, Jeffery A Smisek, Marc Blaustein and Nicholas Haft. View institutional ownership trends. How do I buy shares of Finch Therapeutics Group? Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FNCH) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersWARNING about the death of the U.S. dollar…Colonial MetalsDigitizing the $11T commodities sector with one tiny stockResource Stock DigestBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsPresident Biden just made a shocking moveStansberry ResearchHe Is Giving Away BitcoinCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe Crypto 9-5 Escape PlanCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
